Repso (leflunomide)
- Region
- 🇪🇺 EU
- Active substance
- leflunomide
- Company
- Teva B.V.
- Status
- Withdrawn
- Therapeutic area
- Arthritis, Rheumatoid; Arthritis, Psoriatic
- EU approval
- Mon 14 Mar 2011
- Designations
- Generic
- Application
- EMEA/H/C/001222
- ATC
- L04AA13
- Official record
- www.ema.europa.eu
Indication
Leflunomide is indicated for the treatment of adult patients with: active rheumatoid arthritis as a ‘disease-modifying antirheumatic drug’ (DMARD); active psoriatic arthritis. Recent or concurrent treatment with hepatotoxic or haematotoxic DMARDs (e.g. methotrexate) may result in an increased risk of serious adverse reactions; therefore, the initiation of leflunomide treatment has to be carefully considered regarding these benefit / risk aspects. Moreover, switching from leflunomide to another DMARD without following the washout procedure may also increase the risk of serious adverse reactions even for a long time after the switching.
Regulatory milestones
No milestones recorded in the last year.
Same substance in other markets
- 🇪🇺 Leflunomide Zentiva (previously Leflunomide Winthrop) Authorised · Zentiva k.s.
- 🇪🇺 Arava Authorised · Sanofi-aventis Deutschland GmbH
- 🇪🇺 Leflunomide medac Authorised · medac Gesellschaft für klinische Spezialpräparate mbH
- 🇪🇺 Leflunomide ratiopharm Authorised · Ratiopharm GmbH
- 🇪🇺 Leflunomide Teva Lapsed · Teva Pharma B.V.
Follow Repso
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.